Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Increases By 26.0%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 202,066 shares, an increase of 26.0% from the January 15th total of 160,347 shares. Based on an average daily volume of 66,811 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.0% of the shares of the stock are short sold. Approximately 2.0% of the shares of the stock are short sold. Based on an average daily volume of 66,811 shares, the days-to-cover ratio is presently 3.0 days.

Insiders Place Their Bets

In other Cocrystal Pharma news, Director Phillip Md Et Al Frost bought 50,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was acquired at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director directly owned 1,888,551 shares of the company’s stock, valued at $1,794,123.45. This represents a 2.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders acquired 209,000 shares of company stock valued at $200,210. Company insiders own 28.14% of the company’s stock.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma at the end of the most recent reporting period. 6.72% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.

Cocrystal Pharma Stock Performance

Cocrystal Pharma stock opened at $0.96 on Monday. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67. The firm has a market capitalization of $13.30 million, a price-to-earnings ratio of -1.03 and a beta of 1.20. The company has a 50 day moving average price of $1.02 and a 200 day moving average price of $1.19.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. Equities analysts forecast that Cocrystal Pharma will post -1.85 earnings per share for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.